WillItSurvive
Pharma and healthcare groups · Belgium

UCB

ucb.com ↗

Belgian drugmaker selling BIMZELX and other treatments for immune and neuro diseases.

Hard to displace
Assessed 24 July 2026 · Evidence as of 24 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 24 July 2026 · Checkable from Q1 2027 · Every call on the record Checkpoint: 2027 earnings showing whether icotrokinra and zasocitinib cut into BIMZELX sales growth
The call

UCB's growth rides almost entirely on one injectable drug with patent protection into 2037, while new oral pills from bigger rivals start reaching the market.

UCB makes specialty medicines, particularly BIMZELX, an injection that treats immune diseases. It is hard to copy because government patents protect the drug until 2037 and it takes years of testing to prove a new medicine works. However, newer pill-form competitors like icotrokinra and zasocitinib could convince patients and doctors to switch away from BIMZELX in the next few years. If those pills take over faster than UCB can launch new treatments or expand BIMZELX to new diseases, the company's profits could shrink significantly.

Why
01
AI pressure: None apparent. AI can speed up drug discovery work but cannot skip clinical trials or regulatory approval, so it does not threaten UCB's sales directly. Could AI do the core job? Unlikely.
02
Bigger players: Johnson & Johnson (icotrokinra, oral IL-23R) and Bristol Myers Squibb / Sun Pharma (TYK2 inhibitors like zasocitinib). Rivals are pushing oral pills as alternatives to BIMZELX's injections; icotrokinra got approved March 2026 and could pull patients away. Could a giant copy it? No, they are blocked.
03
What protects it. Patents on BIMZELX run to 2037, UCB just won a patent case, and switching patients off a working injectable is slow and doctor-driven.
What would change this call
Icotrokinra (approved Mar 2026) and zasocitinib (filed 2026) sales figures in 2027 earnings. Would show whether oral drugs are pulling patients away from BIMZELX.
UCB's 2027 BIMZELX growth rate compared to 2025's +200% YoY pace. A sharp slowdown would signal oral disruptors gaining real market share.
Outcome of UCB v. Cipla Federal Circuit appeal and Rubicon Delaware suit. A loss would weaken BIMZELX patent protection before 2032.
Key numbers
  • FY2025 revenue €7.741B, up 26% (2025-12-31)
  • BIMZELX sales ~€2.2B, up ~200% YoY (2025-12-31)
  • Five growth drugs combined pass €3.3B (2025-12-31)
Named risks
  • Oral IL-23R and TYK2 inhibitors (icotrokinra, zasocitinib) could erode BIMZELX's injectable market share starting 2027. Severity: medium
  • Revenue growth heavily concentrated in BIMZELX within the five growth-driver medicines, creating concentration risk. Severity: medium
  • Active patent litigation (UCB v. Rubicon, UCB v. Cipla appeal) could affect generic entry timing if UCB loses. Severity: medium
  • STACCATO alprazolam Phase 3 results delayed to H2 2026, pipeline execution risk. Severity: low
  • Pediatric Phase 3 trials for bimekizumab now running; any safety signal could damage franchise. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
AbbVie (Skyrizi)gaining onBIMZELX outperformed Skyrizi head-to-head in psoriatic arthritis, March 2026 BE BOLD trial
Novartis (Cosentyx)gaining onBIMZELX sales nearly tripled in 2025 versus Cosentyx's roughly $6B 2025 sales
Icotrokinra (oral IL-23R, rival pipeline)contestingOral competitor approved March 2026, targeting same injectable-biologic patient class as BIMZELX
Zasocitinib (oral TYK2, rival pipeline)contestingNDA filed 2026, positioned as oral alternative to BIMZELX and similar injectables
Eli Lilly (Taltz)gaining onTaltz posted about $3.2B in 2024 sales versus BIMZELX's ~200% YoY growth to ~2.2B euros in 2025
J&J (Tremfya)gaining onTremfya reported about $4.06B in sales versus BIMZELX's accelerating 2025 growth
Questions people ask
Is UCB profitable in 2025?
Yes. UCB reported FY2025 revenue of 7.741 billion euros, up 26% reported (29% at constant currency), with net sales of 7.388 billion euros, up 32%, per its February 26, 2026 full-year results press release.
What is UCB's biggest competitor?
In immunology, UCB's BIMZELX competes directly with AbbVie's Skyrizi (projected ~$17.3B 2025 sales) and Novartis's Cosentyx (~$6B 2025 sales); a March 2026 head-to-head trial showed BIMZELX outperforming Skyrizi in psoriatic arthritis.
Could AI replace UCB's drug discovery process?
No, not currently. UCB uses AI tools like its April 2026 DARC antibody-design platform with University of Southampton to speed discovery, but regulatory approval, clinical trials, and patents (BIMZELX protected to 2037) remain human/institutional processes AI cannot bypass.
Who owns UCB?
UCB is publicly traded on Euronext Brussels; its controlling shareholder is Financiere de Tubize SA, linked to the founding Janssen family, holding roughly 36.28% of voting rights as of an October 2025 shareholding disclosure.
How fast is BIMZELX growing for UCB?
BIMZELX net sales reached approximately 2.2 to 2.227 billion euros in 2025, up roughly 200% year-on-year, with US sales of about 1.657 billion euros, according to UCB's FY2025 Facts and Figures document published February 2026.
Are oral drugs a threat to UCB's BIMZELX?
Potentially. Oral IL-23R inhibitor icotrokinra was approved March 2026 and TYK2 inhibitor zasocitinib had an NDA filed in 2026, both targeting the same injectable-biologic market as BIMZELX, though no material share erosion has been reported as of mid-2026.
Timeline
  • 2026-04Launched DARC AI antibody-design platform with University of Southampton
  • 2026-03BE BOLD trial showed BIMZELX outperformed AbbVie Skyrizi in psoriatic arthritis
  • 2026-03Oral IL-23R inhibitor icotrokinra (rival) approved, targeting same patient class as BIMZELX
  • 2026-02-26Reported FY2025 revenue of 7.741 billion euros, up 26%
  • 2026-01KYGEVVI received EU CHMP positive opinion
  • 2025-12Multi-year AI patient-data partnership launched with Citizen Health
  • 2025-11KYGEVVI approved in US, first treatment for TK2 deficiency
  • 2025-01BIMZELX 320mg high-dose formulation launched in US
  • 2025Divested China neurology/allergy portfolio for 488 million euros income
  • 2024-10FDA approved BIMZELX 320mg high-dose formulation
Revision history
24 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources